Aurinia Pharmaceuticals Inc Quick Ratio (AUPH) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Aurinia Pharmaceuticals Inc   (NASDAQ: AUPH)

Aurinia Pharmaceuticals Inc 's Quick Ratio

AUPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.36 below Aurinia Pharmaceuticals Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 326 other companies have achieved higher Quick Ratio than Aurinia Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1697, from total ranking in the second quarter 2026 at 2781.

Explain Quick Ratio?
How much Cash & cash equivalents AUPH´s has?
What are AUPH´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AUPH/financial-strength
https://api.csimarket.com/api/v1/companies/AUPH/fundamentals
https://api.csimarket.com/api/v1/companies/AUPH/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
AUPH Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 2.16 %
Y / Y Cash & cash equivalent Change -37.18 %
Quick Ratio MRQ 0.36
AUPH's Total Ranking # 1697
Seq. Current Liabilities Change -1.13 %
Seq. Cash & cash equivalent Change -74.52 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 327
Healthcare Sector # 579
Overall Market # 1697


Quick Ratio Statistics
High Average Low
27.09 8.71 0.28
0   (Mar 31 2026)




Financial Statements
Aurinia Pharmaceuticals Inc 's Current Liabilities $ 128 Millions Visit AUPH's Balance sheet
Aurinia Pharmaceuticals Inc 's Cash & cash equivalent $ 46 Millions Visit AUPH's Balance sheet
Source of AUPH's Sales Visit AUPH's Sales by Geography


Cumulative Aurinia Pharmaceuticals Inc 's Quick Ratio

AUPH's Quick Ratio for the trailling 12 Months

AUPH Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 3.69 %
Y / Y Cash & cash equivalent TTM Growth 25.83 %
Quick Ratio TTM 0.65
Total Ranking TTM # 3950
Seq. Current Liabilities TTM Growth 0.51 %
Seq. Cash & cash equivalent TTM Growth -7.25 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $127.63 millions, cumulative Quick Ratio decreased to 0.65 below the Aurinia Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Aurinia Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3890 to 3950.

Explain Quick Ratio?
How much Cash & cash equivalents AUPH´s has?
What are AUPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 437
Healthcare Sector # 893
Within the Market # 3950


trailing twelve months Quick Ratio Statistics
High Average Low
27.09 4.87 0.6
(Dec 31 2019)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Akebia Therapeutics Inc   0.98 $ 159.254  Millions$ 162.349  Millions
Acadia Pharmaceuticals Inc   0.97 $ 322.365  Millions$ 332.217  Millions
Alkermes Plc   0.97 $ 631.314  Millions$ 651.933  Millions
Geron Corporation  0.94 $ 69.794  Millions$ 74.248  Millions
Mirum Pharmaceuticals Inc   0.86 $ 243.188  Millions$ 283.080  Millions
Amphastar Pharmaceuticals Inc   0.86 $ 262.786  Millions$ 306.303  Millions
Aclaris Therapeutics Inc   0.84 $ 20.394  Millions$ 24.222  Millions
Seres Therapeutics Inc   0.84 $ 17.528  Millions$ 20.893  Millions
Jazz Pharmaceuticals Plc  0.80 $ 2,036.400  Millions$ 2,540.300  Millions
Zomedica Corp   0.80 $ 7.281  Millions$ 9.096  Millions
Pfizer Inc  0.79 $ 25,140.000  Millions$ 31,726.000  Millions
Xencor Inc  0.78 $ 59.622  Millions$ 76.266  Millions
Janux Therapeutics Inc   0.77 $ 41.818  Millions$ 54.247  Millions
Arcus Biosciences Inc   0.76 $ 151.000  Millions$ 199.000  Millions
Ligand Pharmaceuticals Incorporated  0.75 $ 374.303  Millions$ 500.569  Millions
Ionis Pharmaceuticals Inc   0.68 $ 296.303  Millions$ 435.292  Millions
Liquidia Corporation  0.68 $ 396.091  Millions$ 585.397  Millions
Bristol myers Squibb Company  0.67 $ 12,581.000  Millions$ 18,753.000  Millions
Harrow Inc   0.66 $ 75.336  Millions$ 114.224  Millions
Supernus Pharmaceuticals inc   0.62 $ 176.171  Millions$ 285.397  Millions
Axsome Therapeutics Inc   0.62 $ 313.859  Millions$ 509.719  Millions
Travere Therapeutics Inc   0.59 $ 123.542  Millions$ 210.912  Millions
Clene Inc   0.58 $ 9.887  Millions$ 17.114  Millions
Zoetis Inc   0.57 $ 1,533.000  Millions$ 2,682.000  Millions
Organon and Co   0.55 $ 1,455.000  Millions$ 2,652.000  Millions
Medicus Pharma Ltd   0.52 $ 5.020  Millions$ 9.743  Millions
Gossamer Bio Inc   0.51 $ 51.189  Millions$ 99.945  Millions
Bausch Health Companies Inc   0.51 $ 2,485.000  Millions$ 4,895.000  Millions
Neonc Technologies Holdings Inc   0.49 $ 10.966  Millions$ 22.241  Millions
Inovio Pharmaceuticals Inc   0.48 $ 49.786  Millions$ 102.842  Millions

Date modified: 2026-10-31T17:30:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.